Enthalpic Efficiency of Ligand Binding

The thermodynamics of ligand-protein binding has received much attention recently. In the present contribution we focus on the enthalpic component of binding. The dissociation constant, pK(d), was decomposed into enthalpic and entropic components (pK(d) = pK(H) + pK(S)), and pK(H), defined as pK(H) = -ΔH/(2.303·RT) was used to characterize the enthalpy contribution to binding. It was found that the maximal achievable pK(H) decreases with increasing molecular size. This is in contrast to maximal pK(d) that increases with molecular size until it achieves a plateau. Size-independent enthalpic efficiency (SIHE) was defined as SIHE = pK(H)/40·HA(0.3), with HA being the number of heavy atoms. SIHE allows a size unbiased comparative binding characterization of compounds. It can find use in hit and lead selection and also in monitoring optimization in drug discovery programs. The physical background of decreasing maximal pK(H) with molecular size is discussed, and its consequences to drug discovery are analyzed. It is concluded that the feasibility of simultaneous optimization of affinity and enthalpy diminishes with increasing molecular size. Consequently, binding thermodynamics considerations are to be applied primarily in hit prioritization and hit-to-lead optimization.

[1]  Je Ladbury,et al.  Enthalpic efficiency and the role of thermodynamic data in drug development: possibility or a pipeline dream! , 2007 .

[2]  K. P. Murphy,et al.  Energetics of hydrogen bonding in proteins: A model compound study , 1996, Protein science : a publication of the Protein Society.

[3]  Gennady M Verkhivker,et al.  Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[5]  A. Schuffenhauer,et al.  Complex molecules: do they add value? , 2005, Current opinion in chemical biology.

[6]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[7]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[8]  Samy O Meroueh,et al.  PDBcal: A Comprehensive Dataset for Receptor–Ligand Interactions with Three‐dimensional Structures and Binding Thermodynamics from Isothermal Titration Calorimetry , 2008, Chemical biology & drug design.

[9]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[10]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[11]  S. Bembenek,et al.  Ligand binding efficiency: trends, physical basis, and implications. , 2008, Journal of medicinal chemistry.

[12]  György G Ferenczy,et al.  Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.

[13]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[14]  Tudor I. Oprea,et al.  Is There a Difference Between Leads and Drugs? A Historical Perspective. , 2001 .

[15]  N. Powell,et al.  Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. , 2007, Bioorganic & medicinal chemistry.

[16]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[17]  Dan C. Fara,et al.  Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..

[18]  Graham F. Smith Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. , 2009, Progress in medicinal chemistry.

[19]  Heather A Carlson,et al.  Differences between high- and low-affinity complexes of enzymes and nonenzymes. , 2008, Journal of medicinal chemistry.

[20]  Gerhard Klebe,et al.  Adding calorimetric data to decision making in lead discovery: a hot tip , 2010, Nature Reviews Drug Discovery.

[21]  J. Willem M. Nissink,et al.  Simple Size-Independent Measure of Ligand Efficiency , 2009, J. Chem. Inf. Model..

[22]  N. Powell,et al.  Binding thermodynamics of substituted diaminopyrimidine renin inhibitors. , 2007, Analytical biochemistry.

[23]  Richard Morphy,et al.  The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.

[24]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[26]  Brett A Tounge,et al.  The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.